Published in N Engl J Med on April 15, 1971
The antiphospholipid-thrombosis syndromes. Fact, fiction, confusion, and controversy. Am J Clin Pathol (1993) 1.93
Alterations of hemostasis associated with malignancy: etiology, pathophysiology, diagnosis and management. Semin Thromb Hemost (1978) 1.22
Antithrombin III(AT-III) as a diagnostic aid in disseminated intravascular coagulation. Thromb Res (1977) 1.13
An update on heparins at the beginning of the new millennium. Semin Thromb Hemost (2000) 0.95
A new two-stage functional assay for antithrombin-III (heparin cofactor): clinical and laboratory evaluation. Thromb Res (1976) 0.92
Hemostasis defects associated with cardiac surgery, prosthetic devices, and other extracorporeal circuits. Semin Thromb Hemost (1985) 0.92
Heparin-induced thrombocytopenia, paradoxical thromboembolism, and other side effects of heparin therapy. Med Clin North Am (1998) 0.91
Hydroxyethyl starch versus albumin in cardiopulmonary bypass prime solutions. Ann Thorac Surg (1983) 0.85
Histiocytic medullary reticulosis in two Chinese women. West J Med (1974) 0.84
Antithrombin III patterns in disseminated intravascular coagulation. Am J Clin Pathol (1980) 0.84
Hereditary and acquired thrombophilia. Part I. Preface. Semin Thromb Hemost (1999) 0.84
In-vivo platelet inhibition by piracetam. Lancet (1979) 0.83
Antithrombin agents as anticoagulants and antithrombotics: implications in drug development. Semin Hematol (1999) 0.83
Fibrinolytic activity in acute myocardial infarction. Am J Clin Pathol (1972) 0.83
Laboratory modalities for assessing hemostasis during cardiopulmonary bypass. Semin Thromb Hemost (1976) 0.82
Bleeding times, platelet adhesion, and aspirin. Am J Clin Pathol (1976) 0.82
Alterations of hemostasis associated with cardiopulmonary bypass: pathophysiology, prevention, diagnosis, and management. Semin Thromb Hemost (1976) 0.82
Thrombotic thrombocytopenic purpura. An extended editorial. Semin Thromb Hemost (1979) 0.81
Anemia of malignancy. Hematol Oncol Clin North Am (1996) 0.81
Vascular damage correlates between heparin-induced thrombocytopenia and the antiphospholipid syndrome. Clin Appl Thromb Hemost (1999) 0.81
Laboratory evaluation of antithrombin III: a critical overview of currently available methods for antithrombin III measurements. Semin Thromb Hemost (1982) 0.80
Clinical use of intrapulmonary heparin. Semin Thromb Hemost (1985) 0.80
Antithrombin III and factor VIII in patients with neoplasms. Am J Clin Pathol (1978) 0.79
Disseminated intravascular coagulation and related syndromes: etiology, pathophysiology, diagnosis, and management. Am J Hematol (1978) 0.79
Clinical relevance of antithrombin III. Semin Thromb Hemost (1982) 0.79
Contaminants in heparins continue to be unfolded. Int Angiol (2008) 0.79
The clinical significance of fibrinogen degradation products. Semin Thromb Hemost (1982) 0.78
Deep vein thrombosis. Diagnosis and management. Med Clin North Am (1994) 0.77
Prothrombin complex concentrate: use in controlling the hemorrhagic diathesis of chronic liver disease. Am J Dig Dis (1975) 0.77
Hemostatic defects induced by cardiopulmonary bypass. Vasc Surg (1976) 0.77
Malaria in drug addicts. JAMA (1971) 0.76
Acquired defects of fibrinolysis associated with thrombosis. Semin Thromb Hemost (1999) 0.76
Treatment of hereditary and acquired thrombophilic disorders. Semin Thromb Hemost (1999) 0.76
The rheological changes after cesarean section: The influence of low molecular weight or unfractionated heparin on the rheological properties of blood. Clin Hemorheol Microcirc (2007) 0.76
General and family practice-epitomes of progress: new hope for patients with psoriasis. West J Med (1977) 0.75
Malaria transmission among narcotic addicts. A report of ten cases and review of the literature. Calif Med (1971) 0.75
Antiphospholipid antibodies in coronary artery disease: a review. Semin Thromb Hemost (1994) 0.75
Alterations of hemostasis associated with cardiopulmonary bypass. Thromb Res (1976) 0.75
Vascular disorders associated with thrombohemorrhagic phenomena. Semin Thromb Hemost (1979) 0.75
Impact of automation on the quantitation of low molecular weight markers of hemostatic defects. Semin Thromb Hemost (1983) 0.75
Antithrombin agents: the new class of anticoagulant and antithrombotic drugs. Clin Appl Thromb Hemost (1999) 0.75
Disseminated intravascular coagulation and blood component therapy. Transfusion (1976) 0.75
Letter: Prothrombin complex concentrates and chronic liver disease. Thromb Diath Haemorrh (1975) 0.75
Disseminated intravascular coagulation: a clinical/laboratory study of 48 patients. Ann N Y Acad Sci (1981) 0.75
Current trends in the development of anticoagulant and antithrombotic drugs. Med Clin North Am (1994) 0.75
Fibrinolytic potential in polycythemia rubra vera. Beitr Pathol (1974) 0.75
Daunomycin and fibrinolysis. Thromb Res (1976) 0.75
Diagnostic efficacy of a simple radioimmunoassay test for fibrinogen/fibrin fragments containing the B beta 15-42 sequence. Semin Thromb Hemost (1984) 0.75
Laboratory diagnosis of antiphospholipid syndromes. Clin Lab Med (1995) 0.75
A comparative study of the DuPont antithrombin III and fibrinogen assay systems. Am J Clin Pathol (1985) 0.75
Preliminary report on the use of CCNU (NSC-79037), adriamycin (NSC-123127), and hexamethylmelamine (NSC-13875) in carcinoma of the lung. Cancer Treat Rep (1976) 0.75
Prothrombin G20210A gene mutation, heparin cofactor II defects, primary (essential) thrombocythemia, and thrombohemorrhagic manifestations. Semin Thromb Hemost (1999) 0.75
Adriamycin and fibrinolysis. Thromb Res (1976) 0.75
Surgical hemostasis with a factor XL-containing concentrate. JAMA (1974) 0.75
Thrombogenesis in myocardial infarction and related syndromes: the role of molecular markers in diagnosis and management. Clin Appl Thromb Hemost (1999) 0.75
The clinical relevance of plasminogen activator assays. Am J Clin Pathol (1989) 0.75
Radioimmunoassay. West J Med (1975) 0.75
Fibrinolytic activity. Changes induced with oral contraceptives. Obstet Gynecol (1972) 0.75
Fatal purpura fulminans following total cardiopulmonary bypass. J Cardiovasc Surg (Torino) (1974) 0.75
Antithrombin agents as anticoagulants and antithrombotics. Implications in drug development. Med Clin North Am (1998) 0.75
Antithrombins and coronary artery disease. Am J Clin Pathol (1984) 0.75
Molecular markers of hemostatic disorders: implications in the diagnosis and therapeutic management of thrombotic and bleeding disorders. Clin Chem (1983) 0.75
Letter: Prothrombin complex concentrates and chronic liver disease. Thromb Res (1975) 0.75
Discrepant AT-III and fibrinogen levels on the DuPont acaTM system. Am J Clin Pathol (1983) 0.75
Drug-induced alterations of hemostasis and fibrinolysis. Hematol Oncol Clin North Am (1992) 0.75
Hereditary hemorrhagic telangiectasia and disseminated intravascular coagulation: a new clinical syndrome. Ann N Y Acad Sci (1981) 0.75
The effect of pinealectomy and environmental lighting on the gonadal, thyroid, and total body weight of female Long-Evans rats. Experientia (1969) 0.75
Clinical implications of molecular markers in hemostasis and thrombosis. Semin Thromb Hemost (1984) 0.75
Fully automated antithrombin-III assays by synthetic substrate on the Multistat III. Am J Clin Pathol (1987) 0.75
Molecular markers of hemostatic activation. Implications in the diagnosis of thrombosis, vascular, and cardiovascular disorders. Clin Lab Med (1995) 0.75
Role of antithrombin III in clinical management of pulmonary embolization. Am J Med (1984) 0.75
Clinical hemostasis practice: the major impact of laboratory automation. Semin Thromb Hemost (1983) 0.75
Factor V: a simplified one-stage using a stabilized artificial substrate. Beitr Pathol (1973) 0.75
Biological antithrombin III levels. JAMA (1978) 0.75
Evidence for a new activation phase clotting abnormality in a patient with the Hughes-Stoven syndrome. Beitr Pathol (1974) 0.75